FOLH1 and pachyonychia congenita: Additionally, we’ve to address new developments in targeted molecular imaging techniques with F18-Choline (14,15) and various PSMA (prostate-specific membrane antigen) Positron-Emission-Tomography (PET) scans (16,17) which will most probably be added to the routine clinical management of the patients with PC and recurrent disease in the near future with possible targeted therapeutic implications (17) and also have a significant effect on the use of bone scintigraphy in this patient group (18).